Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chubb
US Army
QuintilesIMS
Chinese Patent Office
McKesson
Boehringer Ingelheim
Cerilliant
Baxter

Generated: July 17, 2018

DrugPatentWatch Database Preview

Tolmar Company Profile

« Back to Dashboard

Summary for Tolmar
International Patents:67
US Patents:10
Tradenames:22
Ingredients:22
NDAs:31
Patent Litigation for Tolmar: See patent lawsuits for Tolmar

Drugs and US Patents for Tolmar

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021731-001 Dec 14, 2004 RX Yes Yes 9,914,802 ➤ Sign Up Y Y ➤ Sign Up
Tolmar CALCIPOTRIENE calcipotriene CREAM;TOPICAL 200935-001 May 30, 2012 AB RX No No ➤ Sign Up ➤ Sign Up
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021379-001 Jul 24, 2002 RX Yes Yes 6,773,714 ➤ Sign Up Y ➤ Sign Up
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021379-001 Jul 24, 2002 RX Yes Yes 6,565,874 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Tolmar

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021379-001 Jul 24, 2002 5,599,552 ➤ Sign Up
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021379-001 Jul 24, 2002 5,739,176 ➤ Sign Up
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021343-001 Jan 23, 2002 5,733,950 ➤ Sign Up
Tolmar Therap ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021343-001 Jan 23, 2002 5,739,176 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Tolmar

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,143,314 Controlled release liquid delivery compositions with low initial drug burst ➤ Sign Up
6,630,155 Controlled release liquid delivery compositions with low initial drug burst ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Tolmar Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB99/003 United Kingdom ➤ Sign Up PRODUCT NAME: IMIQUIMOD; REGISTERED: UK EU/1/98/080/001 19980918
2008 00029 Denmark ➤ Sign Up PRODUCT NAME: ADAPALEN, BENZOYLPEROXID
C0042 Belgium ➤ Sign Up PRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121
269 Luxembourg ➤ Sign Up PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Harvard Business School
Medtronic
Baxter
Citi
Federal Trade Commission
Teva
Johnson and Johnson
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.